节点文献

印度药品专利强制许可制度及对我国的启示

India’s Compulsory Licensing System for Drug Patents and Its Enlightenment to China

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 周亮亮田侃姚银蓥喻小勇杨毅陈步伟卫陈赵文敏

【Author】 ZHOU Liang-liang;TIAN Kan;YAO Yin-ying;YU Xiao-yong;YANG Yi;CHEN Bu-wei;WEI Chen;ZHAO Wen-min;School of Health Economics and Management,Nanjing University of Chinese Medicine;The School of the Public Health of Fudan University;Party Committee Office of Jiangsu Women and Children Health Hosptial;

【通讯作者】 田侃;

【机构】 南京中医药大学卫生经济管理学院复旦大学公共卫生学院江苏省妇幼保健院党政办

【摘要】 药品专利强制许可制度对印度本国医药产业从简单的模仿国外专利药品到能够独立自主研发新药起到了巨大的作用。对印度药品强制许可制度进行概述并对其政策效应进行评价,为我国药品专利强制许可制度设计与执行提供借鉴。我国需始终以人民健康利益为中心,进一步理顺药品专利强制许可制度的实施路径,明确专利强制许可各方的权利及义务,提升重大公共安全卫生等紧急情况下的应对能力,完善药品供应保障以及价格管理、医保补偿等配套制度。

【Abstract】 The compulsory licensing system for drug patents has played a huge role in India’s domestic pharmaceutical industry from simply imitating foreign patented drugs to being able to independently develop new drugs.By summarizing India’s compulsory drug licensing system and evaluating its policy effects,this paper hopes to provide reference for the design and implementation of China’s compulsory drug licensing system.China needs to always take the people’s health interests as the center,further rationalize the implementation path of the compulsory patent licensing system for drugs,clarify the rights and obligations of all parties to the compulsory patent licensing system,improve the response capacity under major public safety and health emergencies,and improve the drug supply,price management,medical insurance compensation and other supporting systems.

【基金】 国家中医药管理局委托项目(GZY-FJS-2018-112)
  • 【文献出处】 南京中医药大学学报(社会科学版) ,Journal of Nanjing University of Traditional Chinese Medicine(Social Science Edition) , 编辑部邮箱 ,2019年01期
  • 【分类号】D913
  • 【被引频次】9
  • 【下载频次】939
节点文献中: 

本文链接的文献网络图示:

本文的引文网络